Introduction

International guidelines recommend endoscopic submucosal dissection (ESD) for en-bloc resection of rectal lesions suspected of submucosal invasive cancer (SMI). ESD achieves favorable outcomes for benign lesions and early rectal cancers (ERC) with superficial (<1000μm) SMI. However, for ERCs with deep (≥1000μm) SMI, the rate of histologically radical (R0) resection remains suboptimal, at maximum 64% for SM2-3 lesions, even in expert centres. The muscle-retracting sign (MRS) has emerged as a potential endoscopic marker of deep SMI detected during endoscopic resection. Predicting deep SMI is particularly relevant in rectal lesions, as incorrect selection of resection modality may lead to non-radical endoscopic resections and the need for surgical salvage, which carries significant morbidity. To address some of these limitations, we applied the novel pocket-detection method (PDM) for MRS detection. This approach enhances visualization of the submucosal space and facilitates early identification of the MRS.

Aims & Methods

The aim of this study was to evaluate the diagnostic accuracy of the MRS detected using the PDM as an innovative approach for identifying deeply invasive ERC during endoscopic resection of rectal lesions.
In this prospective, observational, single-centre study consecutive rectal lesions that underwent endoscopic resection using the PDM between August 2023 and March 2025 were included. Directionality of initial submucosal dissection targeted any morphological or surface vascular pattern at risk of deep SMI to attempt MRS identification. Histopathology was the reference standard for MRS diagnostic accuracy in detecting deep SMI. Deep SMI was defined as ≥1000μm invasion from the muscularis mucosa at histopathology.

Results

38 rectal lesions, median size 30 mm (IQR 20-40), were included. PDM for MRS detection was successful in all cases, with MRS-positive in 15/38 (39.5%). Deep SMI was confirmed in 15/38 (39.5%). Accuracy of MRS-positive for deep SMI detection was 84.2%, (95% CI 69.6-92.6%), sensitivity 80% (95% CI 54.8-92.9%), specificity 87% (95% CI 67.9-95.5%), positive predictive value 80% (95% CI 54.8-92.9%), negative predictive value 87% (95% CI 67.9-95.5%), positive likelihood ratio 6.13, negative likelihood ratio 0.23, area under the curve 0.83 (95% CI: 0.71–0.96). The rate of R0 resection was 92.1% (35/38).

Conclusion

MRS detected using the PDM demonstrated moderate-to-high accuracy in predicting deep SMI in early rectal cancer. This finding may allow selection of endoscopic resection strategy based on invasion depth.

Introduction

Minocycline is considered the most potent semi-synthetic tetracycline, demonstrates promising pharmacokinetic and antimicrobial properties against Helicobacter pylori (H. pylori). While previous studies suggested the efficacy of minocycline-containing bismuth quadruple therapy for H. pylori eradication, real-world evidence remains limited.

Aims & Methods

his study aimed to evaluate the clinical efficacy, safety, and cost-effectiveness of minocycline-containing bismuth quadruple therapy in routine clinical practice.This multicenter, real-world observational study was conducted at 25 hospitals in Fujian China between January and March 2025. Patients diagnosed with H. pylori infection received one of three 14-day bismuth-containing quadruple regimens with b.i.d. esomeprazole 20 mg and bismuth 220 mg, plus amoxicillin 1000 mg b.i.d. and clarithromycin 250 mg b.i.d. (PBAC), or minocycline 100 mg b.i.d. and clarithromycin 250 mg b.i.d. (PBMC), or minocycline 100 mg twice b.i.d. and levofloxacin 500mg q.d. (PBML). The primary outcome was the H. pylori eradication rate, secondary outcomes included the frequency of adverse events, patient compliance, and cost-effectiveness.

Results

A total of 347 patients were enrolled, with 110 patients completing treatment in each group. In the intention-to-treat (ITT) analysis, eradication rates were 77.4% (PBAC), 85.5% (PBMC), and 84.3% (PBML). In the per-protocol (PP) analysis, eradication rates were 80.9%, 90.9%, and 88.2%, respectively. Although the differences among the three regimens were not statistically significant, minocycline-based regimens achieved numerically higher eradication rates. Adverse event incidence was 32.73%, 20.91%, and 23.64% in the three groups, respectively. Compliance rates exceeded 94% across all groups. Cost-effectiveness analysis showed PBML had the lowest cost-effectiveness ratio (5.38 CNY per 1% eradication), followed by PBAC (5.41 CNY) and PBMC (6.06 CNY).

Conclusion

H. pylori eradication, with favorable patient compliance and pharmacoeconomic profiles. These regimens present a viable alternative to traditional amoxicillin-or tetracycline-based therapies. Further large-scale randomized controlled trials are warranted to confirm these findings.

Introduction

Post endoscopy upper gastrointestinal cancers (PEUGIC) are often missed opportunities to diagnose earlier or even prevent cancer. Up to 71% of PEUGIC are potentially avoidable, but identifying and investigating them can be challenging. A national process for identifying all PEUGIC in the English National Health Service and performing root cause analysis was developed.

Aims & Methods

Potential PEUGIC between 2017 and 2023 occurring 3-36 months after an index endoscopy which did not result in a cancer diagnosis were identified from National Cancer Registration Dataset and Hospital Episode Statistics held by the National Cancer Registration and Analysis Service. Data from local root cause analysis were uploaded onto a secure portal for national analysis. PEUGIC following surveillance endoscopies were excluded from this analysis. Logistic regression analysis was used to identify associations with outcomes of interest.

Results

3151 potential PEUGIC were examined by local reviewers in 144 English hospitals. 635 (20%) were excluded on local review and data were available for 2516 PEUGIC. 1897 (75.4%) PEUGIC followed diagnostic, follow-up or screening endoscopies. PEUGIC sites were oesophagus 61%, stomach 34% and duodenum 5%.
Table 1 shows the summary PEUGIC root cause results analysis based on the World Endoscopy Organisation categorisation. Categories C and D were associated with poor outcomes with 29% and 23% of cases receiving curative treatment, respectively. Compared to categories A and B receiving curative treatment in 53% and 37% of cases, respectively. Squamous cell cancers accounted for 37.5% of oesophageal PEUGIC and were associated with no lesion being detected (category C or D) in the PEUGIC segment OR 1.71 (95% CI 1.21-2.43).
Findings on index endoscopy (category A or B) at later oesophageal PEUGIC: pre-malignant lesion 23% (e.g. Barrett’s), cancer associated lesion 20% (e.g. ulcer) and other oesophageal focal lesions 15%. Findings on index endoscopy in gastric PEUGIC: cancer associated lesion 26%, pre-malignant lesion 7% and other gastric focal lesions 18%. 45% of the index endoscopies were classified as inadequate. Patient harm and adverse treatment outcomes were associated with an inadequate index endoscopy OR 1.56 (95% CI 1.28-1.91). The most common reason for inadequate endoscopy was inadequate management of lesions identified, which were most likely to be cancer associated lesions OR 1.43 (95% CI 1.11-1.69), specifically oesophageal strictures (24%) and gastric ulcers (23%).
Gastric diagnostic PEUGIC were diagnosed with more advanced cancer (40% stage 4 at diagnosis vs 30% oesophageal PEUGIC). Treatment following cancer diagnosis was adversely affected in 42% of PEUGIC. Reviewers considered that 57% of PEUGIC were at least possibly avoidable and 9% led to premature death.

Table 1 Root causes of all diagnostic PEUGIC

Conclusion

Abnormalities in the area of the later cancer were detected at index endoscopy in 59% of PEUGIC. Inadequate lesion assessment, endoscopy and/or decision making was noted in 45% of PEUGIC, which adversely affected treatment outcome. Oesophageal squamous cell cancer was a common cause of PEUGIC, suggesting issues with lesion recognition in this cancer. Many patients had incurable disease when diagnosed and treatment was adversely affected in 42%.

Introduction

Recent advances in large language models, such as GPT-4.0 and GPT-4.5, have increased the accessibility of artificial intelligence (AI) in clinical settings. However, its role in decision-making remains unclear.

Aims & Methods

This study compares the appropriateness of esophagogastroduodenoscopy (EGD) prescriptions across ten clinical scenarios, as evaluated by gastroenterology specialists, residents, general practitioners, and five AI systems (ChatGPT-4.0, ChatGPT-4.5, Gemini, Claude, and OpenEvidence), using ESGE and ASGE guidelines as the reference standard. A cross-sectional survey was developed using 10 real-world clinical vignettes in gastroenterology, each with three response options: appropriate, inappropriate, or uncertain. The vignettes were developed based on real-world clinical practices by three expert gastroenterologists, and then reviewed by the authors.The final questionnaire was hosted on Google Forms and simultaneously distributed—without prior notice—to gastroenterology specialists, residents, and general practitioners across Italy to minimize external influence. The same clinical scenarios were then submitted to five AI systems (ChatGPT-4.0, ChatGPT-4.5, Gemini, Claude, and OpenEvidence) using the same multiple-choice format. AI responses were collected on April 22, 2025.

Results

A total of 122 healthcare professionals participated in the study (61% male; mean age 39.7 ± 13.6), including 41 gastroenterology specialists, 31 residents, and 50 general practitioners. Most participants were from northern Italy (76%), with additional representation from central (14%) and southern regions (10%), covering a total of 10 regions. The majority had less than 5 years of clinical experience (66%) and were employed in public hospitals (49%). Only 30% reported prior use of AI in clinical practice. All respondents considered the clinical scenarios realistic.
The average accuracy rate was highest among gastroenterologists (65.6% ± 11.6) and residents (64.8% ± 10.0), compared to general practitioners (56.8% ± 11.0), with statistically significant differences (p < 0.001 and p < 0.005, respectively).
Among AI systems, OpenEvidence and Gemini outperformed all human groups (80% and 80%, p < 0.001), while ChatGPT-4.0 (70%) and Claude (60%) showed comparable performance to clinicians. Notably, ChatGPT-4.5 (50%) underperformed relative to all human categories.

Conclusion

This study highlights significant variability in the appropriateness of upper GI endoscopy prescriptions among different medical professionals, with gastroenterologists performing better than general practitioners. Emerging AI models, particularly OpenEvidence and GEMINI, demonstrated promising performance in clinical decision-making, outperforming all human groups in certain scenarios. These AI systems could serve as valuable tools to support gastroenterologists and other healthcare professionals, enhancing adherence to evidence-based practices and facilitating more direct consultation of clinical guidelines. Further research is needed to explore the integration of AI into clinical workflows and its potential to refine decision-making in gastroenterology.

References

1) Chang PW, Amini MM, Davis RO, et al. ChatGPT4 Outperforms Endoscopists for Determination of Postcolonoscopy Rescreening and Surveillance Recommendations. Clin Gastroenterol Hepatol. 2024 Sep;22(9):1917-1925.e17. doi: 10.1016/j.cgh.2024.04.022. Epub 2024 May 9. PMID: 38729387.
2) Maida M, Celsa C, Lau LHS, et al. The Application of Large Language Models in Gastroenterology: A Review of the Literature. Cancers (Basel). 2024 Sep 28;16(19):3328. doi: 10.3390/cancers16193328. PMID: 39409948; PMCID: PMC11475222.

Introduction

Endoscopic submucosal dissection (ESD) is being increasingly adopted worldwide for the treatment of colorectal neoplastic lesions. However, its role in patients with inflammatory bowel disease (IBD) remains debatable, particularly due to the increased risk of submucosal fibrosis from chronic inflammation, which can theoretically impact the clinical outcomes of this technique. This study aimed to assess the efficacy and safety of ESD for colorectal neoplastic lesions in IBD patients, comparing Asian and Western settings.

Aims & Methods

A systematic review was conducted by searching MEDLINE and Web of Science until January 2025, in accordance to MOOSE guidelines. We included primary studies reporting ESD performance in IBD patients. We performed random-effects meta-analysis for several outcomes, including en-bloc, R0, and curative resection rates, frequency of adverse events (post-procedural bleeding and perforation), local recurrence and need for additional surgery after ESD. Certainty of evidence was assessed using GRADE.

Results

We included 20 studies (565 patients and 732 lesions). The meta-analytical frequencies of en-bloc, R0, and curative resection rates were 95.7% (95%CI=93.5-97.9%; I²=60.1%), 84.6% (95%CI=79.4-90.1%; I²=68.9%), and 83.9% (95%CI=76.3-92.4%; I²=75.9%), respectively. Bleeding and perforation occurred in 7.0% (95%CI=4.4-11.2%; I²=16.9%) and 7.9% (95%CI=5.3-11.9%; I²=2.4%) of cases, respectively. Local recurrence frequency was 5.3% (95%CI=3.5-7.9%; I²=0%). The meta-analytical need for additional surgery was 13.3% (95%CI=9.5-18.1%; I²=42.5%). No differences were found between Asian and Western studies for any outcome. The certainty of evidence was considered "low" in 4 outcomes and "very low" in the remaining outcomes.

Conclusion

ESD appears feasible and safe for treating IBD-associated colorectal neoplasias. Similar results were observed between Asian and Western studies.

Introduction

Lynch syndrome (LS) is associated with an increased risk of upper gastrointestinal (GI) cancers. While upper GI surveillance is recommended in several guidelines, there remains international variability and ongoing debate regarding its implementation, timing, and extent. This study evaluated the incidence of gastric (GC), duodenal (DC), and jejunal cancers (JC) in LS patients using data from the German Consortium for Familial Intestinal Cancer (GCFIC). In addition, the diagnostic yield of esophagogastroduodenoscopy (EGD) and push enteroscopy (PE), performed at a tertiary care center, was retrospectively analyzed.

Aims & Methods

A total of 960 endoscopic procedures (494 EGD, 466 PE) were retrospectively analyzed in 349 LS patients documented at a tertiary care center. Push enteroscopy (PE) was performed using a colonoscope to allow deeper insertion into the small intestine, enabling inspection of the proximal jejunum. Clinically relevant findings included intestinal metaplasia, Barrett’s esophagus, adenomas, and carcinomas. These findings were systematically compared between EGD and PE to evaluate diagnostic yield. The GCFIC database was evaluated to determine cancer incidence by genotype.

Results

In the GCFIC cohort (n=2859), the majority of GC (2.2%), DC (2.1%), and JC (1.9%) occurred in high-risk pathogenic variant carriers (PGV) (MLH1, MSH2, EPCAM). However, a small proportion of cancers was also observed in low-risk PGV carriers: GC in two MSH6 carriers, DC in five patients with MSH6 or PMS2, and JC in seven low-risk carriers (MSH6: 3, PMS2: 4). In the NZET cohort, 22% of procedures and 50 % of patients revealed relevant findings. Gastric adenomas were found in 3.7%, gastric cancer in 1.1%, and intestinal metaplasia in 28% of patients. Duodenal adenomas were found in 3.7% and cancer in 0.9%. Jejunal neoplasia was detected exclusively by PE (adenomas 1.7%, cancer 0.6%).

Conclusion

Upper gastrointestinal surveillance is essential in patients with Lynch syndrome. Push enteroscopy (PE) provides diagnostic value beyond conventional esophagogastroduodenoscopy (EGD), particularly in detecting jejunal neoplasia, and should be considered in high-risk surveillance protocols.

Disclosure

Robert Hüneburg was funded by Deutsche Krebshilfe (DECADE), and Wilhelm-Sander-Stiftung.
Jacob Nattermann was funded by Wilhelm-Sander-Stiftung.